Cipaglucosidase alfa (Pombiliti®) is accepted for use within NHS Scotland
The Scottish Medicines Consortium has completed its assessment of cipaglucosidase alfa and has advised that this offers an additional treatment choice as a long-term enzyme replacement therapy for the treatment of adults with late onset Pompe, used in combination with the enzyme stabiliser miglustat.
This follows on from the NICE recommendation of cipaglucosidase alfa with miglustat published in August this year.
Further information and the detailed advice document is available on the Scottish Medicines Consortium website:
AGSD-UK submitted evidence as part of the SMC assessment and welcomes the availability of an additional treatment option for adults with late-onset Pompe in Scotland.